Drug intelligence / Profile preview

SBN-3

Development stage: Preclinical
Lead developer: Shenzhen SiBiono GeneTech
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
Administration: Injection

Overview

SBN-3 is a next-generation, dual-gene recombinant oncolytic adenovirus injection developed by Shenzhen SiBiono GeneTech Co., Ltd. for the treatment of various solid tumors. Building upon the technology of Gendicine (the world's first approved gene therapy), SBN-3 is engineered to selectively replicate within tumor cells, leading to direct oncolysis. It simultaneously delivers therapeutic genes, including the p53 tumor suppressor, to induce apoptosis and stimulate a systemic anti-tumor immune response. This multi-pronged approach is designed to provide broad-spectrum anti-cancer activity and is currently in the preclinical stage of development.

Other names: 双基因重组溶瘤腺病毒注射液dual-gene recombinant oncolytic adenovirus injection

Targets

TP53 (Cellular Tumor Antigen p53 R175H)

Beyond the preview

Go deeper on SBN-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBN-3.

Explore the full profile